Ornithine-Transcarbamylase deficiency Market: By Product Type (DTX-301, SEL-313, SHP-641, PRX-OTC, Others) By End User (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Ornithine Transcarbamylase Deficiency Market size was valued at USD 896.6 million in the 2029 market and growing at a CAGR of 3.4% from 2029. Ornithine transcarbamylase deficiency is a hereditary condition that causes ammonia to build up in the blood. It is recognised by the absence of the enzyme ornithine transcarbamylase, which can be full or partial (OTC). The enzyme ornithine transcarbamylase (OTC) is required for the breakdown and elimination of nitrogen in the body. The absence of the OTC enzyme results in an excessive buildup of nitrogen in the blood in the form of ammonia. The most prevalent urea-cycle abnormality is OTC deficiency, which affects one in every 40,000 babies. OTC is caused by a mutation on the X-chromosome. As a result, most women are carriers, whereas their boys who have the gene are affected. Progressive lethargy, vomiting, reluctance to eat, and unconsciousness are all indications of OTC deficiency. Nitrogen scavenging agents can help with this deficit. It is possible to develop an OTC deficit at any age. Males are more commonly affected by this neonatal-onset illness, while females are extremely rare. Certain framework which have to be put on for the production of drugs because there is no FDA (Food and Drug Administration) approved drug that exists for this urea cycle disorder which is considered to be the biggest opportunity for global Ornithine-Transcarbamylase. Market players have witnessed strategic collaboration and acquisition to expand their product portfolio and strengthen their position in the market to enhance the revenue of the company. In Dec 2018- The Food and Drug Administration (FDA) expanded the approval of Ravicti (glycerol phenylbutyrate; Horizon Pharma) a nitrogen-binding agent, which is indicated for the chronic management of urea cycle disorders (UCDs) in adults and children. In April 2020- The San Diego biotech announced it had received the FDA’s permission to enter into the clinic with ARCT-810, an investigational treatment for Ornithine Transcarbamylase (OTC) deficiency.

 

 

Ornithine Transcarbamylase Deficiency Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

3.4%

Largest Market

North America

Fastest Growing Market

North America
Ornithine-Transcarbamylase deficiency market Dynamics

Certain framework which have to be put on for the production of drug because there is no FDA (Food and Drug Administration) approved drug which exists for this urea cycle disorder which is consider to be a biggest opportunity for global Ornithine-Transcarbamylase. It is noticed that the global ornithine-transcarbamylase deficiency market is influenced mainly by increase in the number of people with genetic mutation on X-chromosome. The most effected population is males when compared to the overall population. Most of the treatment cost are out pocket which a normal individual can afford hence government are providing intense funding program to eradicate the Ornithine-Transcarbamylase deficiency. Products include Buphenyl, Ravicti, Ammonul, dietary supplements, and others. This is a life-threatening disorder, which needs extra attention as number of vulnerable people increase during the COVID-19 pandemic because certain medicine ARCT-810 is showing an impressive result on that segment of population. Hence a significant growth can be observed

Ornithine Transcarbamylase Deficiency Market Segmentation

By Product Type
  • DTX-301
  • SEL-313
  • SHP-641
  • PRX-OTC
  • Other
By End User
  • Hospital Pharmacy,
  • Retail Pharmacy
  • Online Pharmacy
By Geography
  • North America
  • Asia Pacific
  • Europe
  • Latin America

Frequently Asked Questions

The ornithine-transcarbamylase deficiency market size was valued at USD 896.6 million in 2022  

Lucane Pharma SA, PhaseRx lnc, Promethera Biosciences SA, Selecta Bioscience Inc, Translate bio Inc, Ultragenyx pharmaceuticals, Unicyte AG, Ucyclyd pharma, Horizon Therapeutics plc

The ornithine transcarbamylase deficiency market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Ornithine Transcarbamylase Deficiency Market Introduction 
2.1.Global Ornithine Transcarbamylase Deficiency Market  - Taxonomy
2.2.Global Ornithine Transcarbamylase Deficiency Market  - Definitions
2.2.1.Product Type 
2.2.2.Geography
2.2.3.Geography
2.2.4.Region
3. Global Ornithine Transcarbamylase Deficiency Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Ornithine Transcarbamylase Deficiency Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Ornithine Transcarbamylase Deficiency Market  By Product Type , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. DTX-301
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. SEL-313
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. SHP-641
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. PRX-OTC
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Other
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6. Global Ornithine Transcarbamylase Deficiency Market  By Geography, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Hospital Pharmacy,
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Retail Pharmacy
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Online Pharmacy
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7. Global Ornithine Transcarbamylase Deficiency Market  By Geography, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Asia Pacific
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Europe
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Latin America
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8. Global Ornithine Transcarbamylase Deficiency Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Ornithine Transcarbamylase Deficiency Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Product Type  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.DTX-301
9.1.2.SEL-313
9.1.3.SHP-641
9.1.4.PRX-OTC
9.1.5.Other
9.2.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Hospital Pharmacy,
9.2.2.Retail Pharmacy
9.2.3.Online Pharmacy
9.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.North America
9.3.2.Asia Pacific
9.3.3.Europe
9.3.4.Latin America
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Ornithine Transcarbamylase Deficiency Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.DTX-301
10.1.2.SEL-313
10.1.3.SHP-641
10.1.4.PRX-OTC
10.1.5.Other
10.2.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hospital Pharmacy,
10.2.2.Retail Pharmacy
10.2.3.Online Pharmacy
10.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.North America
10.3.2.Asia Pacific
10.3.3.Europe
10.3.4.Latin America
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Ornithine Transcarbamylase Deficiency Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.DTX-301
11.1.2.SEL-313
11.1.3.SHP-641
11.1.4.PRX-OTC
11.1.5.Other
11.2.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hospital Pharmacy,
11.2.2.Retail Pharmacy
11.2.3.Online Pharmacy
11.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.North America
11.3.2.Asia Pacific
11.3.3.Europe
11.3.4.Latin America
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Ornithine Transcarbamylase Deficiency Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.DTX-301
12.1.2.SEL-313
12.1.3.SHP-641
12.1.4.PRX-OTC
12.1.5.Other
12.2.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hospital Pharmacy,
12.2.2.Retail Pharmacy
12.2.3.Online Pharmacy
12.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.North America
12.3.2.Asia Pacific
12.3.3.Europe
12.3.4.Latin America
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Ornithine Transcarbamylase Deficiency Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.DTX-301
13.1.2.SEL-313
13.1.3.SHP-641
13.1.4.PRX-OTC
13.1.5.Other
13.2.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Hospital Pharmacy,
13.2.2.Retail Pharmacy
13.2.3.Online Pharmacy
13.3.  Geography Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.North America
13.3.2.Asia Pacific
13.3.3.Europe
13.3.4.Latin America
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Lucane Pharma SA
14.2.2.PhaseRx lnc
14.2.3.Promethera Biosciences SA
14.2.4.Selecta Bioscience Inc
14.2.5.Translate bio Inc
14.2.6.Ultragenyx pharmaceuticals
14.2.7.Unicyte AG
14.2.8.Ucyclyd pharma
14.2.9.Horizon Therapeutics plc
14.2.10.OrphanPacific, Inc.
14.2.11.Altis Endurance LLC
14.2.12.SEQENS GROUP
14.2.13.Baush Health Companies, Inc.
14.2.14.Abbott
15. Research Methodology 
16. Appendix and Abbreviations 
  • Lucane Pharma SA
  • PhaseRx lnc
  • Promethera Biosciences SA
  • Selecta Bioscience Inc
  • Translate bio Inc
  • Ultragenyx pharmaceuticals
  • Unicyte AG
  • Ucyclyd pharma
  • Horizon Therapeutics plc
  • OrphanPacific, Inc.
  • Altis Endurance LLC
  • SEQENS GROUP
  • Baush Health Companies, Inc.
  • Abbott

Adjacent Markets